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Summary
We found IL-6-STAT3 pathway suppresses MHC class
II (MHCII) expression on dendritic cells (DCs) and at-
tenuates T cell activation. Here, we showed that IL-6-
STAT3 signaling reduced intracellular MHCII ab dim-
mer, Ii, and H2-DM levels in DCs. IL-6-mediated STAT3
activation decreased cystatin C level, an endogenous
inhibitor of cathepsins, and enhanced cathepsin activ-
ities. Importantly, cathepsin S inhibitors blocked re-
duction of MHCII ab dimer, Ii, and H2-DM in the IL-6-
treated DCs. Overexpression of cystatin C suppressed
IL-6-STAT3-mediated increase of cathepsin S activity
and reduction of MHCII ab dimer, Ii, and H2-DM levels
in DCs. Cathepsin S overexpression in DCs decreased
intracellular MHCII ab dimer, Ii, and H2-DM levels, LPS-
mediated surface expressionofMHCII and suppressed
CD4+ T cell activation. IL-6-gp130-STAT3 signaling in
vivo decreased cystatin C expression andMHCII ab di-
mer level in DCs. Thus, IL-6-STAT3-mediated increase
of cathepsin S activity reduces the MHCII ab dimer,
Ii, and H2-DM levels in DCs, and suppresses CD4+ T
cell-mediated immune responses.
Introduction
The regulation of MHCII molecules in DCs is a critical
factor in the host defense system and involves activa-
tion of the adaptive immune system (Mellman and Stein-
man, 2001). Newly synthesized MHCII a and b immedi-
ately combine with the invariant chain (Ii) to prevent
endogenous peptides from binding to the MHCII ab di-
*Correspondence: hirano@molonc.med.osaka-u.ac.jpmer in the endoplasmic reticulum (ER). The MHCII-Ii
complex is then transported to lysosomes and endo-
somes and stored as Lamp2+ MHCII vesicles. It is known
that without maturation signals, a limited amount of
MHCII dimers move to the plasma membrane (Pierre
et al., 1997). Maturation signals for DCs, such as TLR-
mediated signaling, induce the intracellular trafficking
of the MHCII vesicles and the increased surface expres-
sion of MHCII (Chow et al., 2002; Trombetta and Mell-
man, 2005). During this process, Ii is cleaved by lyso-
somal proteases to form CLIP, which remains on the
MHCII ab dimer (Pierre and Mellman, 1998; Pierre
et al., 2000). Exogenous antigens engulfed via phagocy-
tosis and endocytosis are also degraded into various
antigen peptides by the lysosomal proteases in DCs.
These antigen peptides bind to MHCII ab dimers after
CLIP is released by H2-DM, an MHC-like molecular
chaperon (Miyazaki et al., 1996). The antigen-peptide
bound MHCII ab dimers then move to the plasma mem-
brane, where they can activate CD4+ T cells. Therefore,
the regulation of lysosomal proteases is critical for the
antigen presentation by MHCII in DCs and for the subse-
quent CD4+ T cell-mediated immune responses (Trom-
betta et al., 2003; Delamarre et al., 2005).
Lysosomal proteases such as cathepsins L, B, and S
play critical roles in immune responses. They are ex-
pressed in various antigen-presenting cells, including
DCs (Honey and Rudensky, 2003). Cathepsin S medi-
ates cleavage of the p22 and p10 Ii fragments, and this
is important for exogenous antigen presentation by
MHCII in DCs (Shi et al., 1999). Several in vivo studies us-
ing knockout mice revealed that cathepsin L is impor-
tant for the positive selection of CD4+ T cells in a manner
dependent on cortical thymic epithelial cells (Nakagawa
et al., 1998). Cathepsin E, but not cathepsins B or D, is
potentially involved in the proteolysis of outer antigens
in the antigen-presentation process (Chain et al.,
2005). Recent studies demonstrated that the acidifica-
tion of lysosomes that is dependent on a vacuolar pro-
ton pump is critical for the cathepsin enzyme activity
in DCs (Trombetta et al., 2003; Chow and Mellman,
2005) and that relatively weak lysosomal protease activ-
ity is crucial for the antigen presentation by DCs, which
can be distinguished from the presentation by macro-
phages (Delamarre et al., 2005).
Several reports describe the roles of proinflammatory
cytokines in regulating cathepsins in various types of
cells, such as macrophages and DCs (Fiebiger et al.,
2001; Beers et al, 2003). IFN-g, TNF-a, and IL-1 upregu-
late cathepsin activities and increase the amount of an-
tigen-peptide bound MHCII after activation. In contrast,
pretreatment with an anti-inflammatory cytokine, IL-10,
inhibits the TNF/IL-1-mediated cathepsin enzyme activ-
ity and downregulates the antigen presentation of MHCII
in DCs (Fiebiger et al., 2001). It was reported that the sig-
nificance of cathepsin S activation in DC maturation,
which is induced by reduction of cystatin C level, enhan-
ces cleavage of Ii chain and allows a larger fraction of
newly synthesized MHCII to reach the cell surface.
They demonstrated that the lower the cystatin C level
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492Figure 1. IL-6-STAT3 Signaling Reduced Intracellular MHCII ab Dimer Level in DCs
(A) Wild-type BMDCs were prepared and stimulated with IL-6 or IL-10. The BMDC lysates were separated by SDS-PAGE, and the SDS-stable
MHCII ab dimer and a-tubulin were detected by Western blotting. We used the a-tubulin-blot as a standard and defined the nonstimulated con-
trols as 100. The surface MHCII (I-Ab) level was measured by FACS after IL-6 and IL-10 treatments. These experiments were performed at least
three times independently, and representative data are shown.
(B) gp130WT/WT, gp130F759/F759, and gp130FxxQ/FxxQ BMDCs were generated and stimulated with IL-6. BMDC lysates were separated by SDS-
PAGE, and SDS-stable MHCII ab dimer (MHCII) was detected by Western blotting. The MHCII ab dimer levels were compared by defining the
non-stimulated control as 100. These experiments were performed three times independently, and representative data are shown. The relative
protein level is shown with error bars indicating 1 SD. The P value was calculated by Student’s t test.
(C) A dominant-negative form of STAT3 (DN-STAT3) was transduced into gp130F759/F759 BMDCs. MHCII ab dimer in the BMDCs was detected by
Western blotting. These experiments were performed three times independently, and representative data are shown. The relative protein level is
shown with error bars indicating 1 SD. The p value was calculated by Student’s t test.compared with that of cathepsin S, the higher the ca-
thepsin S activity in antigen-presenting cells (Pierre
and Mellman, 1998).
Recently, we demonstrated that IL-6, a pleiotropic cy-
tokine that regulates the growth, differentiation, and sur-
vival of a variety of cells (Hirano, 1998), and inhibits DC
maturation through STAT3 activation (Park et al.,
2004). We found that the surface expression of MHCII-
and DC-mediated T cell priming are increased in IL-
6KO mice and decreased in gp130F759/F759 mice, which
bear a gp130 that transduces a higher-than-normal level
of STAT3 signaling (Park et al., 2004). Here, we demon-
strated that the IL-6-STAT3-mediated activation of a ly-
sosomal enzyme, cathepsin S, decreased the intracellu-
lar H2-DM and MHC class II ab dimer levels in DCs,
which attenuated the subsequent CD4+ T cell activation.
Results
IL-6-STAT3 Signaling Reduced the Intracellular SDS
Stable MHCII ab Dimer Level in DCs
To investigate the mechanism of the IL-6-STAT3-medi-
ated suppression of MHCII surface expression in acti-vated DCs, we prepared bone marrow-derived dendritic
cells (BMDCs) from C57BL6 mice and treated them with
IL-6. We hypothesized that the intracellular MHCII level
would be reduced after treatment with IL-6, even in im-
mature DCs. As expected, the simple addition of IL-6
to immature BMDCs decreased the intracellular SDS-
stable MHCII ab dimer level within 24–72 hr (Figure
1A), although the surface expression level of MHCII
was not significantly reduced after IL-6 treatment, as
shown previously (Park et al., 2004 and Figure 1A). IL-
10 treatment on immature BMDCs also decreased the
intracellular SDS-stable MHCII ab dimer level within
24–48 hr (Figure 1A), and the surface expression level
of MHCII was not significantly reduced even after IL-10
treatment like IL-6 (Figure 1A).
An IL-6-signal transducer, gp130, activates two sig-
naling pathways: the Jak/Stat and the SHP2/ERK/MAP
kinase pathways (Fukada et al., 1996; Hirano et al.,
2000, Kamimura et al., 2003). To investigate the in vivo
role of these pathways, we have established two knockin
mouse lines, gp130F759/F759 and gp130FxxQ/FxxQ. The
gp130F759/F759 mice contain a mutant gp130 that does
not recruit SHP2 and SOCS3 at Y759 and shows
STAT3-Cathepsin S Controls MHCII ab Dimer in DCs
493enhanced STAT3 activation, whereas the mutant gp130
in gp130FxxQ/FxxQ mice does not transduce any STAT3-
mediated signal (Ohtani et al., 2000). We prepared
BMDCs from these two mutants. As shown in Figure 1B,
we observed a greater reduction in SDS-stable MHCII ab
dimer in gp130F759/F759 DCs after IL-6 treatment but
a complete blockade of its reduction in gp130FxxQ/FxxQ
DCs, suggesting that STAT3 activation is involved in
the IL-6-mediated reduction of the intracellular SDS-
stable MHCII ab dimer level. We next analyzed whether
STAT3 is critically involved in the reduction in MHCII ab
dimer level after IL-6 treatment. We infected BMDCs
with a retrovirus carrying a dominant-negative form of
STAT3 (DN-STAT3), then stimulated the gp130F759/F759
DCs with IL-6 for 48 hr. The IL-6-mediated reduction in
MHCII ab dimer level was abrogated by the expression
of DN-STAT3 in the BMDCs (Figure 1C). These results
clearly show that the IL-6-mediated reduction in the
SDS-stable MHCII ab dimer level in DCs was dependent
on STAT3.
STAT3 Activation Decreased the H2-DM and
Invariant Chain Levels in DCs after IL-6 Treatment
We next investigated the levels of other MHCII-related
proteins, invariant chain (Ii) and H2-DM, in DCs treated
with IL-6. The Ii and H2-DM levels were both decreased
after IL-6 treatment (Figure 2A). These data suggest
that IL-6 decreased not only the MHCII ab dimer level
but also the Ii and H2-DM levels in DCs. The IL-6-
mediated reduction of H2-DM and Ii was blocked by ex-
pressing DN-STAT3 in BMDCs (Figure 2B), suggesting
that IL-6-STAT3-mediated signaling affects the MHCII
vesicles that contains MHCII ab dimer, Ii, and H2-DM
molecules.
We next investigated whether IL-6 treatment induced
an alteration in the MHCII vesicle positioning in DCs.
Confocal microscopy analysis revealed that IL-6 treat-
ment caused an attenuation of MHCII signals but did
not significantly alter the positioning of MHCII vesicles
in DCs (Figure 2C). MHCII vesicles were still colocalized
with a lysosomal marker, Lamp2, and an MHCII chap-
eron, H2-DM, even after IL-6 treatment (Figure 2C,
data not shown), suggesting that IL-6 treatment does
not cause the MHCII vesicles to separate from lyso-
somes in DCs.
We then analyzed whether IL-6-mediated signaling
decreases the MHCII ab dimer level by inducing its
dissociation into monomers or a degradation of the
MHCII a and b molecules themselves. We performed
a pulse-chase experiment in the presence or absence
of IL-6 for 1 hr and 6 hr, and 35S-labeled MHCII dimers
and monomers were immunoprecipitated with an anti-
MHCII antibody (Y3P) (Driessen et al., 1999; Bryant
and Ploegh, 2004). We then determined the amount of
MHCII ab dimers or total amount of a- and b- chains
as monomers, by performing SDS-PAGE without or
with boiled samples, respectively. The 6 hr treatment
with IL-6 significantly reduced the level of MHCII ab
dimers but not monomers (total amount of MHCII) in
DCs (Figure 2D). These data show that IL-6-mediated
signaling decreased the MHCII ab dimer level but did
not directly induce degradation of the MHCII a and
b chains.STAT3-Dependent Increase of Cathepsin SActivity Is
Involved in the Reduction of MHCII ab Dimer, Ii,
and H2-DM Levels in IL-6-Treated DCs
We demonstrated that the MHCII ab dimer and H2-DM
levels decreased through STAT3 activity after IL-6 treat-
ment. To investigate whether this reduction is controlled
at the transcription level, we performed real-time PCR
and RT-PCR experiments. Both experiments showed
consistent results. As shown in Figures 3A and 3B and
Figure S3 available with the Supplemental Data for this
article online, we observed that the MHCII (I-Aa and
I-Ab), Ii, and H2-DM mRNA levels were almost the same
within 24 hr of IL-6 treatment in gp130F759/F759 DCs, al-
though we noticed a reduction in these mRNAs after
48 hr of IL-6 treatment. Importantly, MHCII ab dimers
significantly decreased within 24 hr of IL-6 treatment in
gp130F759/F759 DCs (Figure 1B). All these data suggested
that the levels of MHCII, Ii, and H2-DM are mainly con-
trolled posttranscriptionally in DCs within 24 hr of IL-6
treatment. Because the status of MHCII molecules is
known to be controlled posttranscriptionally in DCs
(Cella et al., 1997), we hypothesized that a protein deg-
radation pathway is activated after IL-6-mediated
STAT3 activation. Two major pathways are known for
the degradation of intracellular proteins in antigen-pre-
senting cells, including DCs. One is mediated by the
ubiquitin-proteasome system (Rock et al., 2004; Kloet-
zel, 2004) and the other by lysosomal proteases (Naka-
gawa and Rudensky, 1999; Riese and Chapman, 2000;
Ackerman and Cresswell, 2004; Bryant and Ploegh,
2004). We first tested two proteasome inhibitors, epox-
omicin and MG132, and found they had no effect on
the IL-6-mediated reduction of the MHCII ab dimer and
H2-DM levels (data not shown). We next tested the ef-
fect of lysosomal proteases, including cathepsins, on
the reduction of MHCII ab dimer and H2-DM levels in
IL-6-treated DCs.
We employed several inhibitors of cathepsins (Katu-
numa et al., 2003). CLIK060 is a specific inhibitor of ca-
thepsin S (Katunuma et al., 1999), and E64d is a relatively
broad inhibitor of thiol proteases including cathepsin S
(Barrett et al., 1981). Both CLIK060 and E64d signifi-
cantly blocked the IL-6-mediated reduction of MHCII
ab dimer, Ii, and H2-DM levels, although specific inhibi-
tors for cathepsin L and B (Tsuge et al., 1999; Hashimoto
et al., 2001) had no effect on it (Figure 3C). These results
clearly show that cathepsin S activity was responsible
for the IL-6-mediated decrease in MHCII ab dimer, Ii,
and H2-DM levels in DCs. Consistent with this notion,
we found that the activities of cathepsin B, L, and S in-
creased after IL-6 or IL-10 treatment of DCs (Figure
4A), although we understand the assays for cathepsin
activities using synthetic substrates are not all specific.
The IL-6 effect was enhanced in DCs from gp130F759/F759
and abolished in DCs from gp130FxxQ/FxxQ mice, sug-
gesting that STAT3 activation is critical for the IL-6-me-
diated activation of cathepsins. Consistently, DN-STAT3
overexpression significantly blocked the cathepsin B, L,
and S enzyme activities in DCs after IL-6 treatment (Fig-
ure 4B), indicating that IL-6-STAT3 signaling increased
the cathepsin activities in DCs.
We also found that the mRNA levels of cathepsins L
and B increased in DCs via the STAT3 binding sites of
gp130 (data not shown). However, only a small induction
Immunity
494Figure 2. STAT3 Activation after IL-6 Treatment Decreased Not Only SDS Stable MHCII ab Dimer Level but Also H2-DM and Invariant Chain Lev-
els in DCs
(A) gp130F759/F759 BMDCs were generated and stimulated with IL-6. SDS-stable MHCII ab dimer, invariant chain (Ii), and H2-DM were detected by
Western blotting. We defined the nonstimulated control as 100. These experiments were performed three times independently, and represen-
tative data are shown. The relative protein level is shown, with error bars indicating 1 SD.
(B) DN-STAT3 was transduced into gp130F759/F759 BMDCs. Invariant chain (Ii) and H2-DM in the BMDCs were detected by Western blotting.
These experiments were performed three times independently, and representative data are shown. The relative protein level is shown, with error
bars indicating 1 SD.
(C) Localization of MHCII (I-Ab) and Lamp2 in gp130F759/F759 BMDCs was determined by confocal microscopy after IL-6 treatment. Profiles of four
CD11c+ cells in one experimet were shown. A detailed colocalization analysis was performed with the top profiles (arrow heads) using TCS-SP2
(Leica). These experiments were performed five times independently, and representative data are shown.
(D) The time course of SDS-stable MHCII ab dimer and total MHCII (monomers) levels in gp130F759/F759 BMDCs was determined by a pulse and
chase experiment after treatment with IL-6. These experiments were performed three times independently. The average SDS-stable MHCII ab
dimer and total MHCII (monomers) levels are shown, with the dimer and total MHCII (monomers) levels in untreated samples defined as 100. The
relative protein level is shown, with error bars indicating 1 SD.of cathepsin S mRNA was observed, even in gp130F759/
F759 DCs, by IL-6 (data not shown). Together, these re-
sults suggest that the IL-6-STAT3 pathway upregulated
cathepsin enzyme activities in DCs.
IL-6-STAT3-Mediated Suppression of Cystatin Level
Controls Cathepsin Activity and MHCII ab Dimer
Level in DCs
We focused on an endogenous cystein protease inhibi-
tor, cystatin C, because it was reported that the balance
between cystatin C and cathepsin S activities play a crit-
ical role in antigen presentation through MHCII (Pierre
and Mellman, 1998). Interestingly, the mRNA of cystatin
C decreased after the IL-6 or IL-10 treatment of DCs
(Figures 3A, 3B, and 5A). Cystatin C mRNA levels starteddecreasing by 1 hr after IL-6 treatment, suggesting
STAT3 directly suppressed the cystatin C mRNA (data
not shown). Consistent with this hypothesis, the IL-6-
mediated reduction of cystatin C mRNA was enhanced
in gp130F759/F759 but abrogated in gp130FxxQ/FxxQ
BMDCs compared with gp130WT/WT controls (Figure
5C). We also observed the similar results in the case of
its protein level in BMDCs isolated from gp130F759/F759,
gp130FxxQ/FxxQ, and gp130WT/WT mice (Figure 5B). In ad-
dition, the overexpression of DN-STAT3 in gp130F759/F759
DCs significantly suppressed the downregulation of
cystatin C by IL-6 (Figure 5D).
We next investigated whether increase of cystatin C
expression really decreases intracellular cathepsin S ac-
tivity. We introduced cystatin C molecules in DCs by
STAT3-Cathepsin S Controls MHCII ab Dimer in DCs
495Figure 3. Two Cathepsin S Inhibitors Blocked IL-6-Mediated Reduction in MHCII ab Dimer and H2-DM Levels in DCs
(A and B) Wild-type BMDCs were prepared and stimulated with IL-6. Real-time PCR was done. The relative mRNA level of cystatin C, MHCII (I-Ab),
Ii, and H2-DM in each sample is shown. The average mRNA levels of cystatin C, MHCII (I-Ab), Ii, and H2-DM in each sample were calculated by
defining the value obtained for HPRT mRNA level as 100. The average is shown with error bars indicating 1 SD. The p value was calculated by
Student’s t test. These experiments were performed three times independently, and representative data are shown.
(C) gp130F759/F759 BMDCs were generated and stimulated with IL-6 in the presence of inhibitors, CLIK060, E64d, CLIK148, or CA074Me. The
BMDCs were lysed and MHCII ab dimer, Ii, and H2-DM were detected by Western blotting. Three independent experiments were done. The av-
erage protein levels of MHCII ab dimer, Ii, and H2-DM in each sample were calculated by defining the value obtained for BMDCs in the absence of
IL-6 and inhibitors as 100. The average is shown with error bars indicating 1 SD. The p value was calculated by Student’s t test.a retrovirus vectors and showed that 2- to 3-fold in-
crease of cystatin C molecules after transduction (data
not shown). The increase of cystatin C level significantly
suppressed IL-6-mediated enhancement of cathepsin S
activity (Figure 5E) and, importantly, inhibited IL-6-medi-
ated reduction of MHCII ab dimer, Ii, and H2-DM levels in
DCs (Figure 5F). These results suggested that IL-6-
STAT3-mediated alteration of the balance between cys-
tatin C and cathepsin S levels is important for the status
of MHCII ab dimer, Ii, and H2-DM levels in DCs.
Increased Cathepsin S Activity in DCs Reduced
the MHCII ab Dimer, Ii, and H2-DM Levels
and Suppressed CD4+ T Cell Stimulatory Activity
We next investigated whether an increase in cathepsin S
activity in DCs reduced the MHCII ab dimer, Ii, and H2-
DM levels. As shown in Figures 6A and 6B, both the
cathepsin S level and its activity increased after the
transduction of cathepsin S molecules by a retrovirus
vector. As expected, the MHCII ab dimer, Ii, and H2-DM
levels were significantly reduced by the overexpression
of cathepsin S in DCs (Figure 6B). In addition, the LPS-
mediated increase in the surface expression of MHCII
was abrogated by the increased cathepsin S activity inDCs (Figure 6C). Finally, we investigated whether ca-
thepsin S overexpression in DCs reduced the MHCII-
mediated T cell stimulatory activity of these cells.
CD4+ T cells were isolated from a CD4+ TCR transgenic
mouse line (Tamura et al., 2004) and cocultured in the
presence or absence of antigenic peptide with DCs
transduced with cathepsin S. The activation of P25
CD4+ T cells by DCs in the presence of a specific peptide
was monitored by observing IL-2 secretion. IL-2 secre-
tion from the P25 T cells was significantly attenuated in
DCs in which cathepsin S was overexpressed, just as in
IL-6 or IL-10-pretreated DCs (Figure 6D) (Park et al.,
2004 and data not shown). These results are consistent
with the idea that increased cathepsin S activity de-
creased the intracellular MHCII ab dimer level and sup-
pressed the LPS-mediated surface expression of MHCII
ab dimer, thus attenuating the CD4+ T cell stimulatory
activity of DCs after LPS treatment.
IL-6 Stimulation Decreased Cystatin C Expression,
Increased the Cathepsin S Activity, and Reduced
the MHCII ab Dimer Level in DCs In Vivo
We further investigated whether IL-6-mediated signal-
ing reduced the MHCII ab dimer level in vivo. Because
Immunity
496Figure 4. IL-6 Treatment Upregulated Cathepsin Enzyme Activities through STAT3 Activation
(A) Cathepsin B, L, and S activities were analyzed in gp130WT/WT, gp130F759/F759, and gp130FxxQ/FxxQ BMDCs. Each BMDC was treated with IL-6 or
IL-10. Three experiments were carried out and the average is shown, with error bars indicating 1 SD.
(B) DN-STAT3 was transduced into gp130F759/F759 BMDCs. Each BMDC was treated with IL-6. Cathepsin B, L, and S activities were analyzed.
Three experiments were done and the average is shown, with error bars indicating 1 SD.we previously demonstrated that IL-6 is a critical regula-
tor for maintaining the CD11c+ DC phenotype in superfi-
cial lymph nodes (sLNs) (Park et al., 2004) and we here
showed that both IL-6 and IL-10 expressed in the sLNs
(Figure S4), we used DCs from the sLNs of gp130F759/
F759 mice, which have an excess amount of gp130-in-
duced STAT3 activation for the experiments described
below.
We found that the mRNA level of cystatin C decreased
in CD11c-positive populations of the sLNs isolated from
gp130F759/F759 mice (Figure 7A). We next measured the
cathepsin S activity and MHCII ab dimer level in this
population. As shown in Figure 7B, cathepsin S activity
was enhanced in the CD11c+ population from sLNs in
gp130F759/F759 mice. We confirmed that the MHCII ab di-
mer level was significantly reduced in the CD11c+ popu-
lation of sLNs in gp130F759/F759 compared with the dimer
level in that population in wild-type mice (Figure 7C).
Taking these and our in vitro results together, our find-
ings indicate that IL-6-STAT3 signaling downregulated
the MHCII ab dimer level through an upregulation of ca-
thepsin S activity in vivo.
Discussion
Antigen presentation through MHCII in DCs is critical for
CD4+ T cell-mediated immune responses. We recently
found that the IL-6-STAT3 pathway suppresses DC mat-
uration, including the surface expression of MHCII, and
attenuates the CD4+ and CD8+ T cell responses in vivo
and in vitro (Park et al., 2004). Therefore, we next inves-
tigated how STAT3-mediated signaling inhibits the sur-
face expression of MHCII in activated DCs. Here, we
provide evidence that IL-6-STAT3 signaling decreased
the intracellular MHCII ab dimer, Ii, and H2-DM levels
by enhancing the cathepsin S activity in DCs, even be-
fore their activation. These mechanisms explain, at least
in part, how STAT3-mediated signaling suppresses theLPS-mediated surface expression of MHCII in DCs
(Park et al., 2004). Importantly, the present data indicate
that a cathepsin S-mediated decrease in the MHCII ab
dimer level attenuated the CD4+ T cell response.
IL-6-STAT3 signaling decreased not only the MHCII ab
dimer level in DCs, but also the level of MHCII-associ-
ated molecules, Ii and H2-DM (Figures 1 and 2). A similar
result was obtained using IL-10, an anti-inflammatory
cytokine. All MHCII ab dimer, Ii, and H2-DM molecules
are located in the Lamp2-positive late endosomes in
DCs before activation (Figure 2C and data not shown).
Therefore, it is reasonable that the target sites of IL-6-
STAT3 may be on their transcriptions and/or protein
degradation processes. We observed reduction in their
mRNA levels after STAT3 activation by IL-6 or IL-10 for
at least 24 hr was minimum (Figures 3A and 3B and Fig-
ure S3) but observed a significant reduction of their
mRNA levels at 48 hr of IL-6 treatment (Figures 3A and
3B), suggesting that the STAT-3-mediated decrease in
these molecules occurred at least in part at the tran-
script level after 48 hr of IL-6 treatment. In other words,
the status of MHCII molecules is controlled by post-
transcriptionally in DCs before 48 hr of IL-6 treatment.
Therefore, we hypothesized that a protein degrada-
tion pathway is activated after IL-6-mediated STAT3
activation.
We showed that the cystatin C level in DCs was signif-
icantly reduced by IL-6 or IL-10 (Figure 5). Since it was
demonstrated that cystatin C, which inhibits cathepsin
S activity, regulates the surface level of MHCII expres-
sion via Ii degradation in DCs (Pierre and Mellman,
1998) and we showed that overexpression of cystatin
C canceled the STAT3-mediated increase of cathepsin
S activity and decrease of MHCII ab dimer, Ii, and H2-
DM levels in DCs (Figure 5E and 5F), it is reasonable to
ascertain that a STAT3-mediated increase in cathepsin
S activity is at least partly dependent on the reduction
of cystatin C molecules in DCs.
STAT3-Cathepsin S Controls MHCII ab Dimer in DCs
497Figure 5. IL-6-Mediated STAT3 Activation Reduced Cystatin mRNA Level in DCs
(A) Wild-type BMDCs were prepared and stimulated with IL-6 or IL-10. The mRNA level of cystatin C and G3PDH in each sample is analyzed.
These experiments were performed three times independently, and representative data are shown.
(B) Cystatin C protein was detected in gp130F759/F759 BMDCs after IL-6 treatment. We used the a-tubulin blot as a standard and defined the non-
stimulated controls as 100. These experiments were performed 3 times independently, and representative data are shown.
(C) gp130F759/F759 and gp130FxxQ/FxxQ BMDCs were prepared and stimulated by IL-6. The mRNA level of cystatin C and G3PDH in each sample is
shown. These experiments were performed three times independently, and representative data are shown.
(D) DN-STAT3 was transduced into gp130F759/F759 BMDCs. Cystatin C mRNA in BMDCs expressing DN-STAT3 was detected after IL-6 treatment.
These experiments were performed three times independently, and representative data are shown. We calculated the average amount of cys-
tatin C mRNA and defined the value obtained from BMDCs infected with empty vector (Mock) without IL-6 treatment as 100. The relative mRNA
level is shown with error bars indicating 1 SD.
(E and F) Cystatin C was transduced into gp130F759/F759 BMDCs, and the BMDCs were sorted as CD11c+Thy1.1+ cells. Cathepsin S activity was
measured (E). MHCII ab dimer, Ii, and H2-DM levels were measured (F). Three independent experiments were done and the averages are shown,
with error bars indicating 1 SD.It should be pointed out that there must be a certain
amount of cystatin C molecules still, even after treat-
ment of IL-6 in DCs. Cystation C is reported to be se-
creted from DCs (Zavasnik-Bergant et al., 2005). There-
fore, it is reasonable that the preexisting cystatin C
molecules are secreted outside of DCs gradually or di-
gested by intracellular proteases including cathepsins.
How does STAT3-mediated signaling suppress the
transcription of cystatin C? We propose two hypotheses:
(1) some factor(s) that is expressed by STAT3 activation
suppresses the transcription of cystatin C, and (2) STAT3
and other STATs compete for binding sites on the pro-
moter region of cystatin C. We treated DCs with CHX
and then investigated STAT3-mediated suppression of
cystatin C transcript. Pretreatment of CHX almost com-
pletely inhibited the STAT3-mediated suppression of
cystatin C transcript, suggesting that STAT3-mediated
suppression of cystatin C transcript is dependent on
a translational event of some molecule(s) (Figure S1).
Consistent with this, there is no STAT binding site inthe 50-UTR of cystatin C gene (data not shown). It should
be pointed out that the basal cathepsin activity was re-
duced by DN-STAT3 expression (Figure 4B), whereas
the basal level of cystatin C expression was not affected
by DN-STAT3 overexpression (Figure 5D). From these re-
sults, we hypothesized that the basal level of STAT3 ac-
tivation might be important for cystatin C-independent
regulation of cathepsin activities in DCs, although this
possibility remains to be clarified.
The importance of cystatin C-mediated regulation of
cathepsin S activity for MHCII expression in DC is still
controversial. In fact, deficiency of cystatin C showed
no measurable effect on MHCII-mediated antigen pre-
sentation by DCs (El-Sukkari et al., 2003), whereas it is re-
ported cystatin C is regulating activity of cathepsin S that
is critical for maturation of MHCII molecules in DCs
(Pierre and Mellman, 1998). However, our results here
support the latter idea that cystatin C-mediated reg-
ulation of cathepsin S activity is critical for controlling
MHCII expression in DCs. We hypothesize that some
Immunity
498Figure 6. Increased Cathepsin S Activity Decreased Intracellular MHCII ab Dimer Level in DCs
(A) Cathepsin S was transduced into wild-type BMDCs and the BMDCs were sorted as CD11c+Thy1.1+ cells. Cathepsin S activity was measured.
Three independent experiments were done and the averages are shown with error bars indicating 1 SD.
(B) Cathepsin S was transduced into wild-type BMDCs and the BMDCs were sorted. MHCII ab dimer, Ii, H2-DM, and cathepsin S (CatS) levels
were measured. Three independent experiments were carried out and the averages are shown, with error bars indicating 1 SD.
(C) Cathepsin S was transduced into wild-type BMDCs. The BMDCs were incubated with or without LPS and the surface level of MHCII was an-
alyzed. The mean fluorescence intensity (MFI) of CD11c+ BMDCs is indicated. The experiments were performed three times independently, and
representative data are shown.
(D) Cathepsin S was transduced into wild-type BMDCs. The BMDCs were incubated with or without LPS. P25 CD4+ T cells were co-cultured with
the BMDCs in the presence or absence of antigenic-peptide. The activation of P25 CD4+ T cells was monitored by production of IL-2. Three in-
dependent experiments were carried out, and the averages are shown, with error bars indicating 1 SD.redundancy or adaptation mechanism may work in the
mice that have a deficiency of cystatin C. It is reasonable
to think that the more important a molecule (perhaps cys-
tatin C) is to the body, the more likely it is that there will be
a redundancy pathway to compensate for its absence.
Additionally, there are many cystatin family members
(Vray, et al., 2002; Abrahamson, et al., 2003; Katunuma,
et al., 2003) and some of them were regulated by IL-6-
STAT3 pathways like cystatin C (data not shown).
Cathepsin activity in DCs is also regulated by the vac-
uolar ATPase-, proton pump-mediated pH change in ly-
sosomes during maturation (Trombetta et al., 2003). It is
also reported that IL-10 modulates the pH change in
DCs during the activation process (Fiebiger et al.,
2001) and that IL-6 treatment modulates the pH of late
endosomes through vesicle fusion (Drakesmith et al.,
1998). We do not completely exclude the possibility
that STAT3-mediated pH alteration plays a role for a re-modeling of endocytic compartment and/or cathepsin S
activity in DCs. Concerning the role of pH on cathepsin S
activity, it is also reported that cathepsin S functions at
a broad range of pH compared with cathepsins B and
L (Bromme et al., 1993; Petanceska et al., 1996). Consis-
tent with these reports, we showed that the transduction
of cathepsin S molecules alone (without additional IL-6
or IL-10 treatment) increased the cathepsin S activity
in DCs (Figure 6A); decreased the levels of MHCII ab di-
mer, Ii, and H2-DM (Figure 6B); and suppressed the LPS-
mediated surface expression of MHCII (Figure 6C).
Therefore, it is reasonable to propose that cathepsin S
is active even in immature DCs after transduction of ex-
cess amount of cathepsin S molecules, suggesting this
enzyme functions normally at a broad range of pH in
both immature and mature DCs. Thus, it is possible
that the balance between cystatin C and cathepsin S is
critical for the activity of cathepsin S in both immature
STAT3-Cathepsin S Controls MHCII ab Dimer in DCs
499Figure 7. IL-6 Signaling Enhanced Cathepsin
Activity and Reduced MHCII ab Dimer Level
In Vivo
(A) Cystatin C mRNA in CD11c+ population in
sLNs of wild-type and gp130F759/F759 mice
was detected. These experiments were per-
formed 3 times independently, and represen-
tative results are shown. The relative mRNA
level is shown, with error bars indicating 1 SD.
(B and C) The CD11c+ population was sorted
from sLNs of wild-type and gp130F759/F759
mice. Cathepsin S activity (B) and SDS-stable
MHCII ab dimer level (C) were analyzed. Three
independent experiments were performed,
and the average enzyme activity and signal
intensity are shown, with error bars indicating
1 SD. For the MHCII ab dimer level, represen-
tative results from three experiments are
shown.and mature DCs in which vesicular pH would be dramat-
ically changed.
Several lysosomal cysteine proteases, such as cathe-
psins B, H, L, S, C, and K, have been well characterized,
and specific inhibitors of individual cathepsins provide
powerful tools for studying their functions. An irrevers-
ible specific inhibitor of cystein proteases, E64, was de-
rived from epoxysuccinate (Barrett et al., 1981). CA-074,
in which the right side chain of E64 is changed to isoleu-
cylproline, shows the strict and specific inhibition of ca-
thepsin B. Derivatives of L-trans-epoxysuccinate and
aldehyde were designed using a computer-graphic-
based strategy to be specific inhibitors of cathepsin L
(CLIK148) and S (CLIK060) based on differences in their
substrate binding pockets (Tsuge et al., 1999; Katunuma
et al., 1999, 2003). We used these compounds to inhibit
the functions of specific cathepsins in DCs and showed
that the inhibitors for cathepsin S alone suppressed the
IL-6-mediated decrease in Ii, H2-DM, and MHCII ab
dimers in DCs (Figure 3C). Based on these findings and
our experiments in which we overexpressed cathepsin
S in DCs (Figure 6), we concluded that cathepsin S activ-
ity is critical for the IL-6-STAT3 signaling-mediated re-
duction of MHCII ab dimer and H2-DM levels in DCs.
We hypothesized that a primary target of cathepsin S
is H2-DM. This hypothesis is supported by two lines of
evidence. (1) Although we showed that the intracellular
MHCII ab dimer level was decreased by IL-6 in DCs (Fig-
ure 1A), confocal microscopy analysis revealed that the
distribution of MHCII ab dimers was not affected by IL-6
treatment (Figure 2C). MHCII, H2-DM, and cathepsin S
were present in lysosomes (Lamp2-positive compart-
ments) even after the activation of STAT3 (Figure 2C
and data not shown), suggesting that cathepsin S may
act in the same lysosomes as those containing H2-DM
and the MHCII ab dimers. (2) The MHCII ab dimer level,but not total MHCII (monomer level in boiling condition)
level, significantly decreased by STAT3 activation in
DCs (Figure 2D), and the decrease in H2-DM was
much more severe than that of MHCII or Ii (Figures 1A,
2A, and 2B), suggesting that H2-DM is first degraded
by the activation of cathepsin S. Furthermore, we com-
firmed recombinat cathepsin S degradated H2-DM mol-
ecules purified from DCs in vitro (Figure S6). The loss of
H2-DM decreases the antigen loading of MHCII mole-
cules, which causes the dimers to dissociate into mono-
mers, as seen in H2-DM-deficient mice (Martin et al.,
1996; Miyazaki et al. 1996; Wolf et al., 1998).
In summary, we demonstrated that IL-6-STAT3-
mediated signaling increased the cathepsin S activity
by decreasing the cystatin C expression and reduced
the H2-DM and MHCII ab dimer levels in DCs, which sup-
pressed the subsequent CD4+ T cell-mediated immune
responses.
Experimental Procedures
Mice
Establishment of the gp130F759/F759 knockin mouse was described
(Ohtani et al., 2000). To obtain BMDCs from gp130FxxQ/FxxQ mice,
we reconstituted recipient congenic mice with gp130FxxQ/FxxQ fetal
livers as described (Park et al., 2004). P25-TCR transgenic mice
were a gift from Dr. Takatsu (University of Tokyo) (Tamura et al.,
2004). C57BL/6 mice (5–8 weeks) were purchased from SLC (Shi-
zuoka) and CLEA Japan (Tokyo). The mice were maintained under
specific pathogen-free conditions according to the instructions of
Osaka University Medical School and RIKEN’s guidelines.
Antibodies and Reagents
FITC-anti-MHC class II (I-Ab, b chain), anti-MHC class II (I-A/I-E),
APC-anti-CD11c, FITC-anti-CD86, -anti-Lamp2, the Cytofix/cyto-
perm kit, and 7AAD were obtained from BD Pharmingen. APC-
anti-MHC class II (I-A/I-E), was from eBioscience. Anti-H2-DM and
anti-CD74 antibodies were gifts from Dr. Kasai (National Institute
Immunity
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producing CHO cells were from Dr. Sudo (Toray). Phoenix cells
were obtained from Dr. Saito (RIKEN). pMSCV-IRES-Thy1.1 retrovi-
rus vectors were a gift from Dr. Mitchell (University of Kentucky). Hu-
man IL-6 was obtained from Toray, and mouse IL-10 was purchased
from Peprotech. Lysosomal protease inhibitors against cathepsin S
(CLIK060) and cathepsin L (CLIK148) were synthesized as described
(Tsuge et al., 1999; Katunuma et al., 1999; Katunuma et al., 2003).
The inhibitors for cathepsin B (CA074Me) and E64d were purchased
from Peptide Institute. The other chemicals were obtained from
Sigma.
In Vitro Culture of BMDCs
BMDCs were generated as described (Park et al., 2004). We showed
a typical profile of BMDC in the absence or presence of LPS stimu-
lation we used here (Figure S5). Superficial lymph nodes (sLNs)
CD11c+ cells were isolated from the sLNs of C57BL/6, IL-6KO, and
gp130F759/F759 mice using Moflo (DAKO Cytomatioin). The purity of
the CD11+ population was over 97%.
SDS-PAGE and Western Blotting
BMDCs were harvested after IL-6 or IL-10 stimulation (50 ng/mL), and
CD11c+ cells were collected using anti-CD11c antibody-conjugated
magnetic beads (Miltenyi), and the purity was over 90%. Equal num-
bers of cells were lysed with 2ME containing SDS sample buffer. To
detect the SDS-stable MHCII ab dimer, the cell lysate was not boiled,
and for the other experiments, the samples were boiled. The samples
were separated by electrophoresis on 10%–20% gradient-polyacryl-
amide gels (Daiichi Pure Chemicals). The proteins were transferred to
PVDF membranes (Millipore) and detected by ECL (Perkin Elmer).
Signals were normalized to the signal for a-tubulin.
35S-Met Labeling Assay
BMDCs were pulse labeled with 35S-Met (Amersham) for 1 hr. The
cells were treated with IL-6 and chased for 1 and 6 hr. The cells
were harvested and lysed with Tris-buffered saline containing 1%
Triton-X, and MHCII was immunoprecipitated with anti-MHCII anti-
body (Y3P). The precipitates were solubilized with SDS sample
buffer. The SDS-stable MHCII ab dimer was separated by SDS-
PAGE without boiling, and the monomers were detected after boil-
ing. The radioactivity derived from MHCII proteins was detected
and visualized by BAS system (Hitachi).
FACS Analysis
BMDCs were stained with fluorescence-conjugated antibodies and
7AAD. The FACS pattern obtained from the CD11c+7AAD2 popula-
tion is indicated in the Figures.
Confocal Microscopy
BMDCs generated on glass cover slips in 35 mm culture dishes
(Iwaki) were stimulated with IL-6 for 48 hr and fixed with 4% parafor-
maldehyde in PBS. Immunostaining of BDMCs was performed with
permeabilization by BD Perm/Wash Buffer containing antibodies
and 1% BSA. The cells were washed with PBS and mounted with
Mounting Medium (DAKO Cytomation). We used the following anti-
bodies: anti-MHCII, 1:50 dilution; anti-Lamp2, 1:50 dilution. The fluo-
rescence signals were detected with the spectral Confocal Scanning
system (Leica) through a 633/1.4 Oil DIC I lens. Laser lines at 488
and 633 nm were used for the excitation of FITC and APC, and emis-
sions wavelengths were separated by band pass (505–530 nm) and
long pass (650 nm) filters, respectively. The obtained signals were vi-
sualized with TCS-SP2 (Leica). The images were transferred to Pho-
toshop 7.0.
RT-PCR
CD11c+ cells stimulated were sorted with magnetic bead system
(Miltenyi). RT-PCR was performed as described (Park et al., 2004).
The DNAs were specifically amplified at 25 cycles with a thermal cy-
cler system (Perkin Elmer) using the corresponding primer pairs
for MHC class II (I-Ab) (forward, ACAGATTTCTACCCAGCCAAGA;
reverse, TCACAAGAGCTGAGGTGGTG), (I-Aa) (forward, CGGAGGT
GAAGACGACATTG; reverse, CACCTTGGGGCTCAAATCTT), H2-
DM (forward, CCTCTGCCATTGCATTTGAC; rev, GTCACCTGAGCA
CGGTCTCT), invariant chain (Ii) (forward, AGCCACTGGACATGGAAGAC; reverse, TGAGCAAGGAACCTGAAAGG), Cystatin C (forward,
TAAGCAGCTCGTGGCTGGAGTGA; reverse, CTCAGCCCTTAGGCA
TTTTTGCA), SOCS3 (forward, ATGGTCACCCACAGCAAGTTT; re-
verse, TTAAAGTGGAGCATCATACTG),; and G3PDH (forward, TGA
AGGTCGGTGTGAACGGATTTGGC; reverse, CATGTAGGCCATGAG
GTCCACCAC).
Real-Time PCR
The real-time PCR was performed using a SYBR Green PCR Master
Mix (Applied Biosystems), following the manufacturer’s instructions.
The specific primer pairs for MHC class II (I-Ab), Ii, H2-DM, cystatin C
(CysC), SOCS-3, and HPRT were as follows: I-Ab (forward, AGCAGG
TGTGAGTCCTGGTG; reverse, TAGCACTCGCCCTTGAACTG), Ii
(forward, GACCATCACCTCCCAGAACC; reverse, TGGGTCATGT
TGCCGTACTT), CysC (forward, CGCCATACAGGTGGTGAGAG; re-
verse, GGCACGCTGTAGATCTGGAA), H2-DMa (forward, GTCGGT
GGAAAGAGGTTGCT; reverse, CCTCTGCCATTGCATTTGAC), SOCS3
(forward, GCGAGAAGATTCCGCTGGTA; reverse, CGTTGACAGTCT
TCCGACAAA), and HPRT (forward, GATTAGCGATGATGAACCAGG
TT, reverse, CCTCCCATCTCCTTCATGACA). PCR reactions were
performed in the GeneAmp 7000 Sequence Detection System (Ap-
plied Biosystems). Relative amounts of the transcripts were normal-
ized by the HPRT transcript.
Expression of Cathepsin S and DN-STAT3 in BMDCs
Mouse cathepsin S cDNAs were generated by reverse transcription
with total RNA from BMDCs and sequenced. The resulting cDNA
was cloned into pMSCV-IRES-Thy1.1. The pMSCV-DN-STAT3 was
obtained from Dr. Link (Washington University). BMDCs retro vi-
rus-infected were prepared and analyzed as described (Park et al.,
2004). For Western blot analysis, we sorted GFP+ or Thy1.1+ cells
from the retrovirus-infected BMDCs using Moflo. Briefly, retrovirus
infected-BMDCs were harvested by pipetting and stained with
anti-CD11c, 7AAD and anti-Thy1.1 antibodies. The BMDCs gated
by FSC-SSC and 7AAD-CD11c+GFP+ (or Thy1.1+) populations
were sorted by Moflo (DAKO Cytomatioin). The purity was over
95% (Figure S2A). IL-6-mediated expression of SOCS3 mRNA was
significantly inhibited in DCs DN-STAT3 transduced (Figure S2B).
In Vitro Cathepsin Assay
The enzyme activity of cathepsin B, cathepsin B plus L, and cathep-
sin S was measured in vitro as descrived (Tsuge et al., 1999; Katu-
numa et al., 1999; Katunuma et al., 2003).
CD4+ T Cell Activation Assay
Cathepsin S-expressing BMDCs were sorted by Moflo (DAKO Cyto-
mation) and used as antigen-presenting cells (5 3 104/well). P25
CD4+ T cells were prepared by nylon wool column and magnetic
beads (1 3 105/well). P25 peptide (10 mg/mL) was added to the cul-
ture medium (200 mL/well). The mixture was cultured for 48 hr and
the IL-2 production was assayed using an Immunoassay kit (Bio-
source).
Supplemental Data
Supplemental Data include five figures and are available with this ar-
ticle online at http://www.immunity.com/cgi/content/full/23/5/491/
DC1/.
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